The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection
Open accessAbstract
Respiratory syncytial virus (RSV) is an important causative agent of lower respiratory tract infections in infants and elderly individuals. Its fusion (F) protein is critical for virus infection. It is targeted by several investigational antivirals and by palivizumab, a humanized monoclonal antibody used prophylactically in infants considered at high risk of severe RSV disease. ALX-0171 is a trimeric Nanobody that binds the antigenic site II of RSV F protein with subnanomolar affinity. ALX-0171 demonstrated in vitro neutralization superior to that of palivizumab against prototypic RSV subtype A and B strains. Moreover, ALX-0171 completely blocked replication to below the limit of detection for 87% of the viruses tested, whereas palivizumab did so for 18% of the viruses tested at a fixed concentration. Importantly, ALX-0171 was highly effective in reducing both nasal and lung RSV titers when delivered prophylactically or therapeutically directly to the lungs of cotton rats. ALX-0171 represents a potent novel antiviral compound with significant potential to treat RSV-mediated disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Naturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241 · cited 1×
“Nanobodies are therapeutic proteins derived from the heavychain variable domains (VHH) that occur naturally in heavy chain-only immunoglobulins of the Camelidae (18, 19).”
BackgroundNair, H., Nokes, D. J., Gessner, B. D., Dherani, M., Madhi, S. A., Singleton, R. J., O'Brien, K. L., Roca, A., Wright, P. F., Bruce, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60206-1 · Cited by 2,773
The IMpact-RSV Study Group (1998) · Pediatrics · doi:10.1542/peds.102.3.531 · Cited by 1,961
Abagyan, R., & Totrov, M. (1994) · Journal of Molecular Biology · doi:10.1006/jmbi.1994.1052 · Cited by 975
Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody
McLellan, J. S., Chen, M., Leung, S., Graepel, K. W., Du, X., Yang, Y., Zhou, T., Baxa, U., Yasuda, E., Beaumont, T., et al. (2013) · Science · doi:10.1126/science.1234914 · Cited by 883
COMMITTEE ON INFECTIOUS DISEASES AND BRONCHIOLITIS GUIDELINES COMMITTEE, Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., Murray, D. L., Orenstein, W. A., Rathore, M. H., et al. (2014) · Pediatrics · doi:10.1542/peds.2014-1665 · Cited by 771
Zhang, L., Peeples, M. E., Boucher, R. C., Collins, P. L., & Pickles, R. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.11.5654-5666.2002 · Cited by 581
Peret, T. C., Golub, J. A., Anderson, L. J., Hall, C. B., & Schnabel, K. C. (1998) · Journal of General Virology · doi:10.1099/0022-1317-79-9-2221 · Cited by 453
Wu, H., Pfarr, D. S., Johnson, S., Brewah, Y. A., Woods, R. M., Patel, N. K., White, W. I., Young, J. F., & Kiener, P. A. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.02.024 · Cited by 373
Eshaghi, A., Duvvuri, V. R., Lai, R., Nadarajah, J. T., Li, A., Patel, S. N., Low, D. E., & Gubbay, J. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032807 · Cited by 349
Muyldermans, S., Cambillau, C., & Wyns, L. (2001) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(01)01790-x · Cited by 322
Kwakkenbos, M. J., Diehl, S. A., Yasuda, E., Bakker, A. Q., van Geelen, C. M. M., Lukens, M. V., van Bleek, G. M., Widjojoatmodjo, M. N., Bogers, W. M. J. M., Mei, H., et al. (2010) · Nature Medicine · doi:10.1038/nm.2071 · Cited by 300
Malley, R., DeVincenzo, J., Ramilo, O., Dennehy, P. H., Meissner, H. C., Gruber, W. C., Sanchez, P. J., Jafri, H., Balsley, J., Carlin, D., et al. (1998) · The Journal of Infectious Diseases · doi:10.1086/314523 · Cited by 240
Venter, M., Madhi, S. A., Tiemessen, C. T., & Schoub, B. D. (2001) · Journal of General Virology · doi:10.1099/0022-1317-82-9-2117 · Cited by 238
Inhalation Studies: Foundations and Techniques
Kutzman, R. S. (1984) · Environmental Health Perspectives · doi:10.1289/ehp.58-1569427 · Cited by 228
Villenave, R., Thavagnanam, S., Sarlang, S., Parker, J., Douglas, I., Skibinski, G., Heaney, L. G., McKaigue, J. P., Coyle, P. V., Shields, M. D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110203109 · Cited by 205
Self-citationWu, H., Pfarr, D. S., Tang, Y., An, L.-L., Patel, N. K., Watkins, J. D., Huse, W. D., Kiener, P. A., & Young, J. F. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.04.049 · Cited by 204
Hultberg, A., Temperton, N. J., Rosseels, V., Koenders, M., Gonzalez-Pajuelo, M., Schepens, B., Ibañez, L. I., Vanlandschoot, P., Schillemans, J., Saunders, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017665 · Cited by 195
Self-citationStructural basis of respiratory syncytial virus neutralization by motavizumab
McLellan, J. S., Chen, M., Kim, A., Yang, Y., Graham, B. S., & Kwong, P. D. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1723 · Cited by 182
Systematic Review of the Biology and Medical Management of Respiratory Syncytial Virus Infection
Black, C. (2003) · Respiratory Care · doi:10.4187/respcare.03480209 · Cited by 178
García-Barreno, B., Palomo, C., Peñas, C., Delgado, T., Perez-Breña, P., & Melero, J. A. (1989) · Journal of Virology · doi:10.1128/jvi.63.2.925-932.1989 · Cited by 175
Self-citationDesmyter, A., Decanniere, K., Muyldermans, S., & Wyns, L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102107200 · Cited by 168
Prince, G. A., Hemming, V. G., Horswood, R. L., Baron, P. A., & Chanock, R. M. (1987) · Journal of Virology · doi:10.1128/jvi.61.6.1851-1854.1987 · Cited by 146
The development of nanobodies for therapeutic applications.
Bockstaele, F. V., Holz, J.-B., & Revets, H. (2009) · PubMed · Cited by 145
Nanobodies®: New ammunition to battle viruses
Vanlandschoot, P., Stortelers, C., Beirnaert, E., Ibañez, L. I., Schepens, B., Depla, E., & Saelens, X. (2011) · Antiviral Research · doi:10.1016/j.antiviral.2011.09.002 · Cited by 144
Self-citationArbiza, J., Taylor, G., López, J. A., Furze, J. M., Wyld, S. G., Whyte, P., Stott, E. J., Wertz, G. W., Sullender, W. M., Trudel, M., et al. (1992) · Journal of General Virology · doi:10.1099/0022-1317-73-9-2225 · Cited by 141
Self-citationAntigenic Structure of Human Respiratory Syncytial Virus Fusion Glycoprotein
López, J. A., Bustos, R., Örvell, C., Berois, M., Arbiza, J., García‐Barreno, B., & Melero, J. A. (1998) · Journal of Virology · doi:10.1128/jvi.72.8.6922-6928.1998 · Cited by 123
Self-citationHiatt, A., Bohorova, N., Bohorov, O., Goodman, C. A., Kim, D., Pauly, M. H., Velasco, J., Whaley, K. J., Piedra, P. A., Gilbert, B. E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402458111 · Cited by 118
Self-citationImmunoprophylaxis of RSV Infection: Advancing from RSV-IGIV to Palivizumab and Motavizumab
Wu, H., Pfarr, D. S., Losonsky, G. A., & Kiener, P. A. (2007) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-72146-8_4 · Cited by 109
Wennergren, G., & Kristjánsson, S. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00254101 · Cited by 105
Huang, K., Incognito, L., Cheng, X., Ulbrandt, N. D., & Wu, H. (2010) · Journal of Virology · doi:10.1128/jvi.02699-09 · Cited by 101
Villenave, R., O’Donoghue, D., Thavagnanam, S., Touzelet, O., Skibiński, G., Heaney, L. G., McKaigue, J. P., Coyle, P. V., Shields, M. D., & Power, U. F. (2011) · Virology Journal · doi:10.1186/1743-422x-8-43 · Cited by 76
Self-citationInfluence of Respiratory Syncytial Virus Strain Differences on Pathogenesis and Immunity
Melero, J. A., & Moore, M. L. (2013) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-38919-1_3 · Cited by 73
Self-citationTapia, L. I., Shaw, C. A., Aideyan, L. O., Jewell, A. M., Dawson, B., Haq, T. R., & Piedra, P. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090786 · Cited by 66
Self-citationSchepens, B., Ibañez, L. I., Baets, S. D., Hultberg, A., Bogaert, P., Bleser, P. D., Vervalle, F., Verrips, T. C., Melero, J. A., Vandevelde, W., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir622 · Cited by 64
Self-citationMagro, M., Andreu, D., Gómez‐Puertas, P., Melero, J. A., & Palomo, C. (2010) · Journal of Virology · doi:10.1128/jvi.00447-10 · Cited by 59
Self-citationLagos, R., DeVincenzo, J. P., Muñoz, A., Hultquist, M., Suzich, J., Connor, E. M., & Losonsky, G. A. (2009) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181a165e4 · Cited by 57
Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
Mejías, A., & Ramilo (2008) · Biologics · doi:10.2147/btt.s3104 · Cited by 52
Backman, K., Piippo‐Savolainen, E., Ollikainen, H., Koskela, H. O., & Korppi, M. O. (2014) · Acta Paediatrica · doi:10.1111/apa.12662 · Cited by 48
Biology of human respiratory syncytial virus: a review
Aliyu, A. S., Ahmad, A. E.-F., Rogo, L. D., Sale, L., & Idris, H. (2010) · Bayero Journal of Pure and Applied Sciences · doi:10.4314/bajopas.v3i1.58753 · Cited by 2
Cited by
Watson, J. L., Juergens, D., Bennett, N. R., Trippe, B. L., Yim, J., Eisenach, H. E., Ahern, W., Borst, A. J., Ragotte, R. J., Milles, L. F., et al. (2022) · doi:10.1101/2022.12.09.519842 · Cited by 2,369
De novo design of protein structure and function with RFdiffusion
Watson, J. L., Juergens, D., Bennett, N. R., Trippe, B. L., Yim, J., Eisenach, H. E., Ahern, W., Borst, A. J., Ragotte, R. J., Milles, L. F., et al. (2023) · Nature · doi:10.1038/s41586-023-06415-8 · Cited by 2,325
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
The therapeutic potential of nanobodies
Jovčevska, I., & Muyldermans, S. (2020) · BioDrugs · doi:10.1007/s40259-019-00392-z · Cited by 749
Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies
Wrapp, D., De Vlieger, D., Corbett, K. S., Torres, G. M., Wang, N., Van Breedam, W., Roose, K., van Schie, L., Hoffmann, M., Pöhlmann, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.031 · Cited by 610
Metadata
- Authors
- Detalle, L., Stohr, T., Palomo, C., Piedra, P. A., Gilbert, B. E., Mas, V., Millar, A., Power, U. F., Stortelers, C., Allosery, K., Melero, J. A., & Depla, E.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2016-01
- Volume
- 60
- Issue
- 1
- Pages
- 6-13
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2190300929
- Cited by
- 279
- References
- 40
- FWCI
- 11.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.